Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02261883 · ClinicalTrials.gov registry record · Phase 2
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
A Phase 2 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02261883 is a Phase 2 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT02261883, a Phase 2 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
Interventions
- DRUG Placebo
- DRUG IV Remodulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-07-29 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02261883
The ClinicalTrials.gov registry entry for NCT02261883 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02261883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02261883 about?
NCT02261883 is a clinical study titled "Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn". This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
What is the current status of trial NCT02261883?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-07-29. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT02261883?
The interventions under investigation include: Placebo (DRUG), IV Remodulin (DRUG).
Who is sponsoring clinical trial NCT02261883?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.